Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19

Sep 12 2024 08:30

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com

NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial

Sep 12 2024 08:05

Two of the first three patients in the Phase 1 cohort of the Phase 1/2a clinical trial, treated at the highest dose of 6 billion cells per treatment, were found...

Petlab Co. Wins “Dog Dental Care Product of the Year ” In 2024 Pet Innovation Awards

Sep 12 2024 08:00

Annual Awards Program Recognizes The Most Outstanding Companies, Services And Products Within The Rapidly Expanding Pet Industry

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

Sep 12 2024 08:00

BRIDGEWATER, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory...

Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr

Sep 12 2024 08:00

WILMETTE, Ill., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced positive early data...

Sernova Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function

Sep 12 2024 08:00

LONDON, Ontario and BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment...

Acasti to Present at the Life Sciences Investor Forum

Sep 12 2024 08:00

PRINCETON, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that...

Elevar Therapeutics Reports Advances in HCC and Other Oncology Clinical Programs for Rivoceranib Plus Camrelizumab at the European Society for Medical Oncology Congress 2024

Sep 12 2024 08:00

FORT LEE, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., today announced the presentation of three posters at the European Society...

Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN

Sep 12 2024 08:00

BRISBANE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological...

Bispecific Antibody Drug Conjugates Clinical Trials FDA Approval Commercial Launch Market Forecast 2029

Sep 12 2024 07:49

First Bispecific Antibody Drug Conjugate Is Expected To Be Available In Market By 2029 Says Kuick Research

0/5 (0 Reviews)

Don't miss updates from Health Canada and FDA.

If you are looking for the latest regulatory updates or want the newest regulatory requirements guides, please leave your email and we'll keep you posted.